165 related articles for article (PubMed ID: 36169717)
1. One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
Popov A; Henze G; Roumiantseva J; Budanov O; Belevtsev M; Verzhbitskaya T; Boyakova E; Movchan L; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4629-4637. PubMed ID: 36169717
[TBL] [Abstract][Full Text] [Related]
2. A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A; Henze G; Roumiantseva J; Budanov O; Belevtsev M; Verzhbitskaya T; Boyakova E; Movchan L; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
Pediatr Blood Cancer; 2023 Jun; 70(6):e30295. PubMed ID: 36975157
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A; Henze G; Tsaur G; Budanov O; Roumiantseva J; Belevtsev M; Verzhbitskaya T; Movchan L; Lagoyko S; Zharikova L; Olshanskaya Y; Riger T; Valochnik A; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Aleinikova O; Fechina L; Karachunskiy A
Cancer Med; 2024 Apr; 13(8):e7172. PubMed ID: 38651186
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
Mikhailova E; Popov A; Roumiantseva J; Budanov O; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khachatryan L; Pshonkin A; Ponomareva N; Boichenko E; Varfolomeeva S; Dinikina J; Novichkova G; Henze G; Karachunskiy A
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844406
[TBL] [Abstract][Full Text] [Related]
5. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
6. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
9. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
10. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
[TBL] [Abstract][Full Text] [Related]
12. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
15. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
16. A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.
Popov A; Henze G; Roumiantseva J; Bydanov O; Belevtsev M; Verzhbitskaya T; Movchan L; Tsaur G; Lagoyko S; Zharikova L; Myakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067249
[TBL] [Abstract][Full Text] [Related]
17. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
[TBL] [Abstract][Full Text] [Related]
18. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome.
Oliveira E; Costa ES; Ciudad J; Gaipa G; Sedek Ł; Barrena S; Szczepanski T; Buracchi C; Silvestri D; Siqueira PFR; Mello FV; Torres RC; Oliveira LMR; Fay-Neves IVC; Sonneveld E; van der Velden VHJ; Mejstrikova E; Ribera JM; Conter V; Schrappe M; van Dongen JJM; Land MGP; Orfao A;
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804860
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
20. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]